Jo D, Choi SY, Ahn SY, Song J (2025) IGF1 enhances memory function in obese mice and stabilizes the neural structure under insulin resistance via AKT-GSK3-BDNF signaling
It is licensed only for type 2 diabetes mellitus and carries risks including loss of lean muscle mass, gastrointestinal disturbances, fatigue, and potential hypoglycaemia, all of which impair athletic performance and training capacity
Patients who arrive at therapy already eating moderate-sized, balanced meals consistently report a smoother adjustment period
Embracing diversity: The imperative for inclusive clinical trials
The drugs appear to induce weight loss by delaying the emptying of the stomach, making people feel fuller for longer, and reducing cravings for food as well
OR To continue reading Password required to log in Disease-Modifying Therapies The main goal of the treatment of multiple sclerosis (MS) is to decrease relapse frequency and slow the progression of disability